CBIS has a history of Highly Explosive Moves Up!
Cannabis Science, Inc., (PINK: CBIS) was the first medical marijuana penny stock to make epic gains for investors; in early 2012 the stock ran from under a penny to highs near $0.25 per share for 2000% + gains!
Since those heady days, as many other stocks in the sector made huge gains CBIS floundered and formed a base in the $0.05 level. In late 2012 and early 2013 the stock made several runs over $0.10 only to fall right back to the $0.05 base.
In April 2013 CBIS has seen an acceleration in price and volume off the $0.05 base and investors are betting this one goes much higher. Considering the kind of volume that CBIS continues to trade here I would suggest the changes of that are excellent!
On March 27, CBIS announced the appointment of Dr. Michael McGrath MD, PhD, Professor, Departments of Laboratory Medicine, Pathology, and Medicine at The University of California San Francisco (UCSF) to the Company's Scientific Advisory Board. He has authored over 100 scientific articles in the fields of AIDS, cancer and neurological disease since joining UCSF in 1985 and has recurring NIH funding to support his research programs in excess of $1.5M per year.
Oringal Article: NBC News reported; Voters in Colorado and Washington on Tuesday approved measures allowing adults to use marijuana for any purpose, NBC News projected, marking an historic turning point in the slow-growing acceptance of marijuana usage
Marijuana Stocks are heating up again and when that happens we can usually expect an explosion of price and trading volume on Cannabis Science, Inc. (OTC: CBIS) and Medical Marijuana Inc (OTC: MJNA) With a huge influx of buy volume, press releases and media hype CBIS is again breaking north of its trading range with a strong move up over the $0.05 Judging by the stocks trading history of highly successful short term run ups we think this run is far from over and should continue well into next week.
CBIS; a pioneering U.S biotech company developing pharmaceutical cannabis products announced on January 4 that sales for 2012 are forecasted to be $6,846,000 and that they have the potential to increase 10 fold by 2014 to $65M They also announced that preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.
Cannabis Science is entertaining entrance into a number of agreements with academic and private sector clinical research organizations that will facilitate initial studies to demonstrate scientific merit of CSTATI-1 and CS-S/BCC-1 that will predictably translate to human studies within the coming year, as clinical options for this patient population remain limited and the etiology of both aggressive squamous/basel cell carcinomas and Kaposi's sarcoma is poor in immune compromised populations, comparative to other skin cancers.
Conclusion: When CBIS gets hot, it gets really hot and by the looks of it; CBIS just got really hot again. This Company has a lot going for it not the least of which is the NBC News Projections that Voters in Colorado and Washington on Tuesday approved measures allowing adults to use marijuana for any purpose, marking an historic turning point in the slow-growing acceptance of marijuana usage. CBIS has seen some important developments over the last few months as well as rapid growth in revenues the likes of which are rarely seen on the OTCBB. The stock is technically sound and still trades very close to its historical lows. While CBIS is still quite cheap they have developed the type of loyal following that can catapult these penny stocks to 1000% gains. All this Makes CBIS a stock to watch and might just provide a spectacular trade opportunity in the weeks and months ahead!
Please Subscribe to OTCMAGIC right now. Our Stock Picks are Legendary!